首页> 外文期刊>Transplantation Proceedings >Simultaneous liver-kidney transplant for combined renal and hepatic end-stage disease.
【24h】

Simultaneous liver-kidney transplant for combined renal and hepatic end-stage disease.

机译:肝肾联合移植治疗肾脏和肝脏晚期疾病。

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTION: After the first combined liver-kidney transplantation (CLKT) reported by Margreiter in 1984, it became clear that renal failure was no longer an absolute contraindication. OBJECTIVE: Our goal was to assess our results with combined liver-kidney transplant.Among 875 liver transplants performed between May 1986 and October 2002, there were 17 cases (1.96%) of combined liver-kidney transplant. RESULTS: With a mean follow-up of 42.2+/-29 months (range, 1-90), six patients had died (mortality: 37.5%). There were four (25%) operative in-hospital deaths, and two late mortality cases (beyond the month 6 after hospital discharge). The causes were sepsis (four cases, three postoperative and one in later follow-up), refractory heart failure (one postoperative), and recurrent liver disease (HCV-induced severe recurrence) during follow-up one). Actuarial survival (calculated for those who survived the postoperative period) was 80%, 71%, and 60% at 12, 36, and 60 months. Actuarial mean survival time was 60 months (95%IC:47-78). Neither the sex, the UNOS status, the etiology of liver disease, the etiology of renal failure, the type of hepatectomy (piggy back vs others) or the type of immunosuppression (P=.83) were related to long-term survival according to the log-rank test. A control group of 48 patients was constructed with subjects who underwent liver transplantation immediately before or after the combined transplant. A total (two cases after the CLKT and one case prior to). There were no differences in survival. CONCLUSION: Combined liver-kidney transplant represents a proper therapeutic option for patients with simultaneously failing organs based on long- and short-term outcomes.
机译:简介:1984年,玛格丽特(Margreiter)首次报道了肝肾联合移植(CLKT),现在很明显,肾衰竭不再是绝对的禁忌症。目的:我们的目的是评估肝肾联合移植的效果。在1986年5月至2002年10月进行的875例肝移植中,有17例(1.96%)肝肾联合移植。结果:平均随访42.2 +/- 29个月(范围1-90),有6例患者死亡(死亡率:37.5%)。共有4例(25%)手术中院内死亡和2例晚期死亡病例(出院后第6个月以后)。原因包括败血症(4例,术后3例,后续随访1例),顽固性心力衰竭(术后1例),以及随访1期间复发性肝病(HCV引起的严重复发)。在12、36和60个月时,精算存活率(按术后存活者计算)分别为80%,71%和60%。精算平均生存时间为60个月(95%IC:47-78)。性别,UNOS状态,肝病的病因,肾衰竭的病因,肝切除术的类型(背ggy式与其他)或免疫抑制的类型(P = .83)均与长期生存无关。对数等级测试。对照组为48位患者,受试者在联合移植之前或之后接受了肝移植。总计(CLKT之后两个案例,之前一个案例)。生存率无差异。结论:根据长期和短期结果,肝肾联合移植是器官同时衰竭患者的正确治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号